Scoliosis Market

 Market Overview:

The 7 major scoliosis markets reached a value of US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.9 Billion by 2034, exhibiting a growth rate (CAGR) of 3% during 2024-2034.

The scoliosis market has been comprehensively analyzed in IMARC's new report titled "Scoliosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Scoliosis is a medical condition characterized by an abnormal sideways curvature of the spine. In this ailment, the spine may appear to have an "S" or "C" shape, when viewed from the back. The curvature can range from mild to severe and may develop at any age, but it most commonly occurs during the growth spurt just before puberty. Individuals suffering from this illness may experience uneven shoulders or waists, an asymmetrical ribcage, back pain, limited mobility, muscle imbalances, breathing difficulties, postural problems, or discomfort, one shoulder blade being more prominent than the other, etc. The diagnosis of scoliosis usually involves a combination of clinical features and a physical examination, including a visual assessment of the spine and measurements of the curvature with a scoliometer. Several imaging studies, such as magnetic resonance imaging and X-rays, are also utilized in patients to determine structural abnormalities in the spinal cord that may be associated with the underlying indications. The healthcare provider may further perform genetic testing to identify any gene mutations contributing to the condition.

The increasing cases of connective tissue disorders, such as Marfan syndrome, which can weaken the ligaments and tissues that support the spine, are primarily driving the scoliosis market. Furthermore, the rising prevalence of numerous associated risk factors, such as congenital defects, family history, certain neuromuscular conditions, trauma or injury to the spine, etc., is also augmenting the market growth. In addition to this, the inflating utilization of physical therapies, including core stabilization exercises to help in improving posture and flexibility, as well as strengthening the muscles around the affected site, is further creating a positive outlook for the market. Moreover, the widespread adoption of nonsteroidal anti-inflammatory drugs, like ibuprofen, acetaminophen, diclofenac, etc., since they inhibit the production of prostaglandins in the body for managing disease symptoms, such as pain and inflammation, is further bolstering the market growth. Apart from this, the emerging popularity of transcutaneous electrical nerve stimulation techniques to promote better alignment of the spine in patients who are refractory to conventional therapies is expected to drive the scoliosis market in the coming years. 

IMARC Group's new report provides an exhaustive analysis of the scoliosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for scoliosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the scoliosis market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the scoliosis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the scoliosis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current scoliosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the scoliosis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the scoliosis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the scoliosis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of scoliosis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of scoliosis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of scoliosis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with scoliosis across the seven major markets?
• What is the size of the scoliosis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of scoliosis?
• What will be the growth rate of patients across the seven major markets?
   

Scoliosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for scoliosis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the scoliosis market?
• What are the key regulatory events related to the scoliosis market?
• What is the structure of clinical trial landscape by status related to the scoliosis market?
• What is the structure of clinical trial landscape by phase related to the scoliosis market?
• What is the structure of clinical trial landscape by route of administration related to the scoliosis market?